2025年12月7日，国家医疗保障局公布2025年国家医保药品目录调整结果，轩竹生物自主研发的1类创新 药、CDK4/6抑制剂吡洛西利片成功纳入目录，为晚期乳腺癌患者带来医保报销新福利。 智通财经APP获悉，2月13日，恒生指数公司宣布截至2025年12月31日之恒生指数系列季度检讨结果， 其中轩竹生物-B(02575)获纳入恒生综合指数。变动将于2026年3月6日(星期五)收市后实施并于2026年3 月9日(星期一)起生效，届时沪深交易所会相应调整港股通可投资标的范围。据中金研报，轩竹生物有 可能被调入港股通，因其满足了包括市值、流动性和上市时间等在内的一系列标准。 ...

智通财经APP获悉，2月13日，恒生指数公司宣布截至2025年12月31日之恒生指数系列季度检讨结果， 其中劲方医药-B(02595)获纳入恒生综合指数。变动将于2026年3月6日(星期五)收市后实施并于2026年3 月9日(星期一)起生效，届时沪深交易所会相应调整港股通可投资标的范围。据中金研报，劲方医药有 可能被调入港股通，因其满足了包括市值、流动性和上市时间等在内的一系列标准。 交银国际近期发布研报称，首次覆盖劲方医药，给予买入评级，目标价51港元。交银国际表示，作为一 家扎根中国内地、拥有全球视野的创新药企，劲方医药组建了一支平均拥有逾20年行业经验、执行力较 强的核心管理团队，建立了一条包括6款临床阶段候选药物的药物管线。 ...

Group 1 - The company announced that its sixth board meeting was held on February 12, 2026, in two locations: Shandong Province and Shanghai, using a combination of on-site and remote voting methods [1] - The meeting reviewed proposals regarding the acquisition of minority shareholder equity in a controlling subsidiary and related transactions [1] Group 2 - The company experienced a dramatic fluctuation in net profit, increasing ninefold before suddenly reporting a loss exceeding 200 million [1] - The chairman personally contributed 50 million to cover the financial shortfall, raising questions about the company's financial management [1] - There is uncertainty regarding the whereabouts of 5 billion in trust financial products, leading to confusion among shareholders [1]

Core Insights - Bristol Myers Squibb (BMS) reported a total revenue of $48.194 billion for 2025, nearly flat compared to $48.300 billion in 2024, but achieved a significant turnaround in GAAP net profit from a loss of $8.948 billion in 2024 to a profit of $7.054 billion in 2025, with Non-GAAP net profit soaring over 430% from $2.340 billion to $12.545 billion [1][2] Group 1: Financial Performance - The growth product portfolio generated $26.409 billion in revenue, accounting for over 54.8% of total revenue, marking a 17% increase year-over-year [1][3] - Traditional products, including Revlimid and Pomalyst, saw a significant revenue decline of 15%, contributing only $21.785 billion [1][3] Group 2: Product Performance - Revlimid's sales plummeted nearly 49% to $2.951 billion, primarily due to generic competition, with Pomalyst also facing a 54% decline in international sales [3][4] - Eliquis generated $14.443 billion in sales, reflecting an 8% increase, with expectations of 10% to 15% growth in 2026 [4][8] Group 3: Strategic Initiatives - BMS completed five strategic transactions in 2025, including a notable $1.5 billion collaboration with BioNTech to develop a next-generation bispecific antibody [7][8] - The company is shifting its focus from a few blockbuster drugs to a diversified product matrix, with more products exceeding $1 billion in sales [6][8] Group 4: Future Outlook - BMS anticipates a revenue guidance of $46 billion to $47.5 billion for 2026, indicating a cautious outlook amid ongoing challenges from patent expirations [11] - The company is actively pursuing opportunities in cell therapy for autoimmune diseases and expects significant data readouts in 2026 for several key products [9][10]

根据该合作的协议条款，双方将结合英矽智能已验证的AI平台与AI赋能创新药研发能力，以及康哲药 业经验丰富的研发团队和对疾病领域的深度认知，共同推进不少于2个研发项目的合作开发。同时，英 矽智能有望就每个项目获得最高达数千万港元的研发费用支持。 英矽智能2月10日发布公告，集团已与康哲药业达成药物研发战略合作。透过该合作，双方将在中枢神 经系统及自身免疫疾病领域的多个项目上达成一系列由AI赋能的创新药物研发合作。 智通财经APP获悉，2月13日，恒生指数公司宣布截至2025年12月31日之恒生指数系列季度检讨结果， 其中英矽智能(03696)获纳入恒生综合指数。变动将于2026年3月6日(星期五)收市后实施并于2026年3月9 日(星期一)起生效，届时沪深交易所会相应调整港股通可投资标的范围。据中金研报，英矽智能有可能 被调入港股通，因其满足了包括市值、流动性和上市时间等在内的一系列标准。 ...

2月13日，恒生指数公司宣布截至2025年12月31日之恒生指数系列季度检讨结果，其中康臣药业(01681) 获纳入恒生综合指数。变动将于2026年3月6日(星期五)收市后实施并于2026年3月9日(星期一)起生效， 届时沪深交易所会相应调整港股通可投资标的范围。据中金研报，康臣药业有可能被调入港股通，因其 满足了包括市值、流动性和上市时间等在内的一系列标准。 康臣药业此前公告，于2025年6月13日，董事局决议执行股份回购计划，以资金总数不超过2亿港元为 限，于公开市场适时回购股份(先前股份回购计划)。于2026年1月29日，董事局决议根据购回授权进一 步执行另一项股份回购计划，以于公开市场适时回购股份，除先前股份回购计划的资金总数外，额外增 加最多1亿港元(股份回购计划)。据此股份回购计划合计拟动用资金总额将不超过3亿港元。股份回购计 划之期限自本公告日期起至公司下届股东周年大会结束时止或股东于股东大会上撤回或修订购回授权为 止。 ...

Group 1 - The core viewpoint of the news is that Jiuyuan Gene has received acceptance for its clinical trial application for the innovative drug JY54 injection, aimed at weight management in Phase I studies [1] - JY54 injection is a next-generation weight loss therapy that operates through a mechanism similar to insulin, providing multiple metabolic regulation effects [1] - The product is positioned to complement existing GLP-1 products, highlighting the company's strategic extension in the field of metabolic diseases [1] Group 2 - In the recent stock performance, Jiuyuan Gene's share price experienced a fluctuation, reaching a high of 10.35 HKD on February 10 and a low of 9.40 HKD on February 13, with a total decline of 4.39% over the period [2] - Following the announcement, there was a significant increase in trading volume on February 10, with a turnover of 572.71 million HKD, but subsequent trading days saw a decrease in volume [2] - The company repurchased 26,000 shares at a cost of 255,300 HKD on February 12, indicating limited scale in its buyback activity [2]

（文章来源：新京报） 新京报讯（记者刘旭）2月11日，湖北广济药业股份有限公司（简称"广济药业"）发布2026年向特定对 象发行A股股票预案，公司拟向控股股东长江产业集团发行股票募资不超过6亿元，扣除发行费用后将 全部用于偿还借款及补充流动资金。本次发行价格为6.32元/股。 广济药业表示，截至2025年9月30日，公司的资产负债率为62.67%，公司目前较高的资产负债率加大了 公司债务融资的成本，本次发行有利于公司优化资本结构，提高抗风险能力。同时，有利于稳固公司股 权结构，提升公司控制权稳定性；也有利于向社会公众传递积极信息，提升公司投资价值。 2025年10月以来，广济药业董事会曾四次审议通过向银行申请综合授信额度的议案，目的均为实现业务 发展和正常经营所需，包括：向中国民生银行股份有限公司武汉分行申请综合授信1.5亿元，授信期限1 年（其中中长期流动资金贷款支用额度不超过1亿元，期限不超过2年），担保方式为抵押，年利率不超 过3%；向华夏银行黄冈分行申请1.25亿元综合授信，其中1亿元可用于短期流动资金贷款，年利率不超 过2.98%，或开具1.25亿元银行承兑汇票，无抵押担保，资金用途包括采购原材料、 ...

Core Viewpoint - Hubei Guangji Pharmaceutical Co., Ltd. plans to issue up to 94,936,708 A-shares to its controlling shareholder, Changjiang Industrial Investment Group, raising a total of no more than 600 million yuan, which will improve the company's financial status and enhance its resilience against macroeconomic fluctuations [1][3] Group 1: Fundraising and Shareholding Structure - The fundraising will be used to repay loans and supplement working capital, which is expected to improve the company's financial condition [3][5] - After the issuance, Changjiang Industrial Group's shareholding will significantly increase, demonstrating the controlling shareholder's confidence in the company's long-term development [1][3] Group 2: Strategic Positioning and Industry Context - Changjiang Industrial Group is the only provincial-level industrial investment platform in Hubei, focusing on strategic emerging industries, including biomedicine [3][4] - The company aligns with Hubei's "14th Five-Year Plan," which emphasizes the development of high-end medical devices and biomedicine as key growth areas [4] Group 3: Business Structure and Competitive Advantages - Guangji Pharmaceutical is a major global supplier of Vitamin B2, with a market share of approximately 30%, and has a strong operational efficiency and cost control [5][7] - The company has a long history of technological accumulation in Vitamin B2 production, maintaining stable customer relationships and a robust supply chain [7][9] Group 4: Market Trends and Future Outlook - The Vitamin B2 market is entering a down cycle but is expected to recover as global feed demand increases and synthetic biology technology reshapes cost structures [9] - The 600 million yuan fundraising is seen as the beginning of a transformation from a traditional manufacturer to a health platform enterprise [9]

Core Viewpoint - The news summarizes important announcements from various companies, highlighting significant developments in their operations and financial performance. Company Announcements - Tianfeng Securities received a notice from the China Securities Regulatory Commission regarding a case of information disclosure violation related to Fujian Yong'an Forestry Group, and the company will cooperate with the investigation [3] - Southwest Securities plans to raise no more than 6 billion yuan through a private placement to supplement its capital and optimize its capital structure [4] - Qiaoyin Co. has terminated its investment in the artificial intelligence industry headquarters project due to changes in cooperation conditions, with a planned investment of no more than 1 billion yuan [5] - Zongshen Power is planning a major asset swap with Longxin General, aiming to resolve competition issues and promote clearer business development [6] - Laimei Pharmaceutical's selected products for national centralized procurement are expected to generate 106 million yuan in sales for 2024, accounting for 13.35% of the company's revenue [7] Performance Reports - Huayin Technology reported a net profit of 313 million yuan for 2025, a decrease of 24.28%, with revenue of 1.251 billion yuan, up 9.83% [9] - Youlide announced a net profit of 152 million yuan for 2025, down 16.88%, with revenue of 1.221 billion yuan, up 7.99% [10][11] - Fudan Microelectronics reported a net profit of 232 million yuan for 2025, a decline of 59.42%, with revenue of 3.982 billion yuan, up 10.92% [12] - Hanzhong Precision reported a net profit of 470 million yuan for 2025, down 45.54%, with revenue of 2.928 billion yuan, a decrease of 20.32% [13] Shareholding Changes - Gaomei Co.'s controlling shareholder and several directors plan to reduce their holdings by up to 3.19% of the company's shares [15] - Guanghuan New Network's controlling shareholder intends to reduce its stake by up to 3% [16] - ST Yigou's shareholder plans to reduce its holdings by up to 2.5% [17] - Juguang Technology's shareholders plan to collectively reduce their holdings by up to 2.3339% [18] - Xiandai Jidian's shareholder intends to reduce its stake by up to 2.05% [19] - Zhejing Pharmaceutical's shareholders plan to reduce their holdings by up to 1.0385% [21] Contract Signings - China Nuclear Construction signed contracts worth 3.393 billion yuan in January, with total revenue of 7.69 billion yuan [23] - China Chemical signed contracts totaling 36.925 billion yuan in January, including significant contracts over 500 million yuan [24]